Results 21 to 30 of about 1,443,667 (357)

The making of bispecific antibodies [PDF]

mAbs, 2017
During the past two decades we have seen a phenomenal evolution of bispecific antibodies for therapeutic applications. The 'zoo' of bispecific antibodies is populated by many different species, comprising around 100 different formats, including small molecules composed solely of the antigen-binding sites of two antibodies, molecules with an IgG ...
Ulrich Brinkmann, Roland E. Kontermann
openaire   +3 more sources

Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

mAbs, 2021
Bispecific antibodies have recently attracted intense interest. CrossMab technology was described in 2011 as novel approach enabling correct antibody light-chain association with their respective heavy chain in bispecific antibodies, together with ...
Marlena Surowka, Wolfgang Schaefer, Christian Klein   +2 more
doaj   +1 more source

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Cancer Discovery, 2022
Zenocutuzumab, a HER2xHER3 bispecific antibody, reduces cell growth in NRG1-rearranged cancer cell lines and xenografts and induces durable clinical responses in patients with NRG1 fusion–positive tumors.
A. Schram, I. Odintsov, Madelyn Espinosa-Cotton, I. Khodos, W. J. Sisso, M. Mattar, A. Lui, M. Vojnic, Sara H Shameem, Thrusha Chauhan, J. Torrisi, J. Ford, M. O’Connor, C. Geuijen, R. Schackmann, J. J. Lammerts van Bueren, E. Wasserman, E. de Stanchina, E. O’Reilly, M. Ladanyi, A. Drilon, R. Somwar   +21 more
semanticscholar   +1 more source

The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1

Journal of Hematology & Oncology, 2021
Background Therapeutic antibodies targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) axis induce potent and durable anti-tumor responses in multiple types of cancers.
Ming Yi, Jing Zhang, Anping Li, Mengke Niu, Yongxiang Yan, Ying Jiao, S. Luo, P. Zhou, Kongming Wu   +8 more
semanticscholar   +1 more source

Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology

Journal for ImmunoTherapy of Cancer, 2022
With increasing numbers of bispecific antibodies (BsAbs) and multispecific products entering the clinic, recent data highlight immunogenicity as an emerging challenge in the development of such novel biologics.
Yanchen Zhou, H. L. Penny, M. Kroenke, Bianca L. Bautista, Kelly Hainline, Lynette S. Chea, J. Parnes, D. Mytych   +7 more
semanticscholar   +1 more source

Infectious complications of bispecific antibody therapy in patients with multiple myeloma

Blood Cancer Journal, 2022
INTRODUCTION Infection has a significant impact on patients with multiple myeloma (MM) [1]. Bispecific antibody (BsAb) therapy with multiple targets (BCMA, GPRC5D and FCRH5) is increasingly used with good disease response rates [2].
B. Sim, A. Longhitano, J. Er, S. Harrison, M. Slavin, B. Teh   +5 more
semanticscholar   +1 more source

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source

Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma.

Blood Advances, 2021
Cell surface expression levels of GPRC5D, an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cells, which renders it a promising target for immunotherapeutic ...
C. Verkleij, M. Broekmans, M. van Duin, Kristine A Frerichs, R. Kuiper, A. de Jonge, M. Kaiser, G. Morgan, A. Axel, R. Boominathan, J. Sendecki, A. Wong, R. Verona, P. Sonneveld, S. Zweegman, Homer C. Adams, T. Mutis, N. V. D. van de Donk   +17 more
semanticscholar   +1 more source

Single domain based bispecific antibody, Muc1-Bi-1, and its humanized form, Muc1-Bi-2, induce potent cancer cell killing in muc1 positive tumor cells. [PDF]

PLoS ONE, 2018
Muc1 is one of the most studied tumor antigens. However, antibodies or antibody-toxin conjugates against Muc1 have not shown significant efficacy for tumors with Muc1 overexpression.
Yumei Li, Changhua Zhou, Jing Li, Jiayu Liu, Limin Lin, Li Li, Donglin Cao, Qing Li, Zhong Wang   +8 more
doaj   +1 more source

A new approach to produce IgG4-like bispecific antibodies

Scientific Reports, 2021
While achieving rapid developments in recent years, bispecific antibodies are still difficult to design and manufacture, due to mispair of both heavy and light chains. Here we report a novel technology to make bispecific molecules.
Caizhi Zhao, Wei Zhang, Guihua Gong, Liping Xie, Ming-Wei Wang, Youjia Hu   +5 more
doaj   +1 more source